Moderna Valuation
| 0QF Stock | EUR 36.12 1.07 3.05% |
At this time, the firm appears to be overvalued. Moderna secures a last-minute Real Value of €34.68 per share. The latest price of the firm is €36.12. Our model forecasts the value of Moderna from analyzing the firm fundamentals such as Profit Margin of 0.43 %, return on equity of 0.5, and Current Valuation of 69.44 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Moderna's price fluctuation is very steady at this time. Calculation of the real value of Moderna is based on 3 months time horizon. Increasing Moderna's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Moderna stock is determined by what a typical buyer is willing to pay for full or partial control of Moderna. Since Moderna is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Moderna Stock. However, Moderna's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 36.12 | Real 34.68 | Hype 36.12 | Naive 32.84 |
The real value of Moderna Stock, also known as its intrinsic value, is the underlying worth of Moderna Company, which is reflected in its stock price. It is based on Moderna's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Moderna's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Moderna helps investors to forecast how Moderna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Moderna more accurately as focusing exclusively on Moderna's fundamentals will not take into account other important factors: Moderna Total Value Analysis
Moderna is presently estimated to have takeover price of 69.44 B with market capitalization of 50.28 B, debt of 603 M, and cash on hands of 7.99 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Moderna fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
69.44 B | 50.28 B | 603 M | 7.99 B |
Moderna Investor Information
About 68.0% of the company shares are owned by institutions such as pension funds. The book value of Moderna was presently reported as 49.67. The company has Price/Earnings (P/E) ratio of 237.44. Moderna recorded earning per share (EPS) of 22.69. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Moderna's financial statements, Moderna is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Moderna Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Moderna has an asset utilization ratio of 74.5 percent. This implies that the Company is making €0.74 for each dollar of assets. An increasing asset utilization means that Moderna is more efficient with each dollar of assets it utilizes for everyday operations.Moderna Ownership Allocation
Moderna maintains a total of 385 Million outstanding shares. Over half of Moderna's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Moderna. Please watch out for any change in the institutional holdings of Moderna as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Moderna Profitability Analysis
The company reported the revenue of 19.26 B. Net Income was 8.36 B with profit before overhead, payroll, taxes, and interest of 10.55 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Moderna's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Moderna and how it compares across the competition.
About Moderna Valuation
The stock valuation mechanism determines Moderna's current worth on a weekly basis. Our valuation model uses a comparative analysis of Moderna. We calculate exposure to Moderna's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Moderna's related companies.Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people.
8 Steps to conduct Moderna's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Moderna's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Moderna's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Moderna's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Moderna's revenue streams: Identify Moderna's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Moderna's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Moderna's growth potential: Evaluate Moderna's management, business model, and growth potential.
- Determine Moderna's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Moderna's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |